Helen S. Te to Drug Therapy, Combination
This is a "connection" page, showing publications Helen S. Te has written about Drug Therapy, Combination.
Connection Strength
0.175
-
Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety. Dig Dis Sci. 2005 Apr; 50(4):719-26.
Score: 0.055
-
Autoimmune hepatitis: a histological variant associated with prominent centrilobular necrosis. Gut. 1997 Aug; 41(2):269-71.
Score: 0.032
-
Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients. Liver Transpl. 2016 11; 22(11):1536-1543.
Score: 0.031
-
An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014 Dec 18; 371(25):2375-82.
Score: 0.027
-
Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol. 2011 Mar; 106(3):452-8.
Score: 0.020
-
Results of steroid-based therapy for the hepatitis C-autoimmune hepatitis overlap syndrome. Am J Gastroenterol. 2001 Oct; 96(10):2984-91.
Score: 0.011